货号：DT2025061383
CAS：1332075-40-7
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Tirofiban-d9 is deuterium labeled Tirofiban.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Tirofiban-d9 相关抗体:
Fibronectin Antibody (YA762)
Pan-Cadherin Antibody
Paxillin Antibody
Integrin alpha 5 Antibody
Integrin alpha V Antibody
Integrin beta 1 Antibody
Integrin beta 3 Antibody
Fibronectin Antibody
ICAM1 Antibody (YA725)
ICAM1 Antibody (YA352)
VCAM1 Antibody
CD41 Antibody (YA1839)
Fibrinogen gamma Chain Antibody (YA1896)
Fibrinogen alpha Chain Antibody (YA2069)
ELMO1 Antibody (YA2243)
von Willebrand Factor Antibody (YA2406)
Integrin alpha 6 Antibody (YA3020)
Integrin alpha 2 Antibody (YA3107)
Integrin beta 5 Antibody (YA3108)
Integrin beta 6 Antibody (YA3122)
Integrin beta 4 Antibody (YA3280)
Integrin alpha 9 Antibody (YA1660)
alpha Internexin Antibody (YA2067)
Integrin alpha L Antibody (YA2398)
Vitronectin Antibody (YA2402)
MADCAM1 Antibody (YA2744)
ICAM2 Antibody (YA3007)
ICAM3 Antibody (YA3009)
Integrin alpha E Antibody (YA3051)
Integrin Linked ILK Antibody (YA3111)
分子量：449.65
Formula：C22H27D9N2O5S
CAS 号：1332075-40-7
非标记 CAS：144494-65-5
中文名称：替罗非班-d9
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (522 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.
 [Content Brief]
[3]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.
 [Content Brief]
[4]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.
 [Content Brief]
[5]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.
 [Content Brief]
[6]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.
 [Content Brief]